Treatment of hepatocellular carcinoma

Current Treatment Options in Gastroenterology

Volumn 7, Issue 6, 2004, Pages 431-441

  Llovet, Josep M ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; AFLATOXIN; ALCOHOL; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOSTATIC AGENT; DOXORUBICIN; GROWTH FACTOR; INTERFERON; IODINATED POPPYSEED OIL; IODINE 131; MEGESTROL; MITOMYCIN; OCTREOTIDE; ORAL CONTRACEPTIVE AGENT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RECEPTOR BLOCKING AGENT; RETINOID; TAMOXIFEN; THALIDOMIDE; TYROSINE KINASE RECEPTOR; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CATHETER ABLATION; CHEMOEMBOLIZATION; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; EARLY DIAGNOSIS; GENE THERAPY; HEALTH SURVEY; HORMONAL THERAPY; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LIVER ISCHEMIA; LIVER NODULE; LIVER RESECTION; LIVER TRANSPLANTATION; PATHOGENESIS; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

EID: 9744231432     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-004-0002-8     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001, 94: 53-156.
2. El Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340: 45-750.
3. Sangiovanni A, Del Ninno E, Fasani P et al.: Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126: 005-1014.
4. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma: The Lancet 2003, 362:1907-1917.
5. Bruix J, Sherman M, Llovet JM, et al.: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001, 35:421-430.
6. Thorgeirsson S, Grisham J: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31:339-346.
7. Chang MH, Chen CJ, Lai MS, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New Engl J Med 1997, 336:1855-1859.
8. Buendia MA: Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000, 10:185-200.
9. Mor E, Kaspa RT, Sheiner F, Schwartz M: Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998, 129:643-653.
10. Poon RT, Fan ST, Tsang FH, Wong J: Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002, 235:466-486.
11. Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 39:1434-1440.
12. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
13. Livraghi T, Giorgio A, Marin G, et al.: Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995, 197: 01-108.
14. Lencioni R, Pinto F, Armillotta N, et al.: Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997, 7:514-519.
15. Arii S, Yamaoka Y, Futagawa S, et al.: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000, 32:1224-1229.
16. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
17. Llovet JM, Real MI, Montana X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
18. Raoul JL, Guyader D, Bretagne JF, et al.: Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997, 26:1156-1161.
19. Kanematsu T, Furuta T, Takenaka K, et al.: A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989, 10: 8-102.
20. Castells A, Bruix J, Bru C, et al.: Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995, 109:917-922.
21. Bismuth H, Majno P: Hepatobiliary surgery. J Hepatol 2000, 32:208-224.
22. Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000, 356:802-807.
23. Makuuchi M, Kosuge T, Takayama T, et al.: Surgery for small liver cancers. Semin Surg Oncol 1993, 9:298-304.
24. Bruix J, Castells A, Bosch J, et al.: Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996, 111:1018-1022.
25. Schwartz JD, Schwartz M, Mandeli J, Sung M: Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002, 3: 93-603.
26. Lau WY, Leung TW, Ho SK, et al.: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999, 353: 97-801.
27. Muto Y, Moriwaki H, Ninomiya M, et al.: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996, 334:1561-1567.
28. Bismuth H, Majno PE, Adam R: Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999, 19: 11-322.
29. Jonas S, Bechstein WO, Steinmuller T, et al.: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33:1080-1086.
30. Yao FY, Bass NM, Nikolai B, et al.: Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002, 8:873-883.
31. Freeman R, Wiesner R, Harper A, et al.: The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002, 8:851-858.
32. Majno PE, Adam R, Bismuth H, et al.: Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997, 226:688-701.
33. Llovet JM, Mas X, Aponte J, et al.: Cost-effectiveness of adjuvant therapy for hepatocellular carcinoma before liver transplantation. Gut 2002, 50:123-128.
34. Trotter J, Wachs M, Everson G, Kam I: Adult-to-adult transplantation of the right hepatic lobe from living donor. N Engl J Med 2002, 14:1074-1082.
35. Cronin D, Millis M, Siegler M: Transplantation of liver grafts from living donors into adults- too much, too soon. N Engl J Med 2001, 344:1633-1637.
36. Gondolesi GE, Varotti G, Florman SS: Biliary complications in 96 consecutive right lobe living donor transplant recipients. Transplantation 2004, 77:1842-1848.
37. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002, 35: 19-524.
38. Sarasin E. Majno P, Llovet JM: Liver donor liver transplantation for early hepatocellular carcinoma: a cost-effectiveness persepctive. Hepatology 2001, 33:1073-1079.
39. Sala M, Llovet JM, Vilana R, et al.: Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004, In press.
40. Llovet JM, Sala M: Non-surgical therapies for hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004, In press.
41. Lencioni R, Allgaier HP, Cioni D, et al.: Small hepatocellular carcinoma in cirrhosis: randomized controlled trial of radiofrequency termal ablation versus percutaneous ethanol injection. Radiology 2003, 228:235-40.
42. Livraghi T, Goldberg SN, Lazzaroni S: Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999, 210:655-661.
43. Rossi S, Garbagnati F, Lencioni R, et al.: Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000, 217:119-26.
44. Llovet JM, Vilana R, Brú C, et al.: Increased risk of tumor seeding after radiofrequency thermal ablation for single hepatocellular carcinoma, Hepatology 2001, 33:1124-1129.
45. Bruix J, Sala M, Llovet J: Chemoemboliation for hepatocellular carcinoma. Gastroenterology 2004, In press.
46. Group d'Etude et de Traitment du Carcinome Hépatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995, 332:1256-1261.
47. Lo CM, Ngan H, Tso WK, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
48. Multicentre International Liver Tumor Study: Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study. Contraception 1997, 56:275-284.
49. Carr BI, Zajko A, Bron K, et al.: Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol 1997, 24(2 Suppl 6):S6.
50. Fong Y, Kemeny N, Lawrence T: Cancer of the liver and biliary tree. In Cancer. Principles and practices of oncology. Edited by DeVita VT, Hellman S, Rosenberg S. Philadelphia: Lippincott Williams and Wilkins; 2001:1162-1204.